Malta - angleščina - Medicines Authority

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - bimatoprost - eye drops, solution - bimatoprost 0.3 mg/ml - ophthalmologicals

Izrael - angleščina - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg / 1 ml - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide; citric acid monohydrate; sodium chloride; dibasic sodium phosphate heptahydrate; benzalkonium chloride - bimatoprost is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; citric acid monohydrate; water for injections; sodium hydroxide; hydrochloric acid; benzalkonium chloride - bimatoprost is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; dibasic sodium phosphate heptahydrate; citric acid monohydrate; water for injections; sodium chloride; benzalkonium chloride - bimatoprost is indicated for the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - bimatoprost, quantity: 0.3 mg/ml - eye drops, solution - excipient ingredients: citric acid; sodium hydroxide; dibasic sodium phosphate; benzalkonium chloride; sodium chloride; water for injections; hydrochloric acid - the reduction of elevated intraocular pressure, or open angle glaucoma, as first line therapy or monotherapy or as adjunctive therapy to topical beta-blockers.

Izrael - angleščina - Ministry of Health

teva israel ltd - bimatoprost - ophthalmic solution - bimatoprost 0.3 mg / 1 ml - bimatoprost - reduction of elevated intraocular pressure in chronic open angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

aspire pharma ltd - bimatoprost - eye drops - 300microgram/1ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

allergan, inc. - bimatoprost (unii: qxs94885mz) (bimatoprost - unii:qxs94885mz) - bimatoprost 0.1 mg in 1 ml - lumigan ®   (bimatoprost ophthalmic solution) 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. lumigan ®   0.01% is contraindicated in patients with hypersensitivity to bimatoprost or to any of the ingredients [see adverse reactions (6.2) ] . risk summary there are no adequate and well-controlled studies of lumigan ®   (bimatoprost ophthalmic solution) 0.01% administration in pregnant women. there is no increase in the risk of major birth defects or miscarriages based on bimatoprost postmarketing experience. in embryofetal developmental studies, administration of bimatoprost to pregnant mice and rats during organogenesis, resulted in abortion and early delivery at oral doses at least 33 times (mice) or 94 times (rats) the human exposure to bimatoprost 0.03% dosed bilaterally once daily (based on blood area under the curve [auc] levels). these adverse effects were not observed at 2.6 times (mice) and 47 times (rats) the huma

Združene države Amerike - angleščina - NLM (National Library of Medicine)

physicians total care, inc. - bimatoprost (unii: qxs94885mz) (bimatoprost - unii:qxs94885mz) - bimatoprost 0.1 mg in 1 ml - lumigan ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. none pregnancy category c teratogenic effects: in embryo/fetal developmental studies in pregnant mice and rats, abortion was observed at oral doses of bimatoprost which achieved at least 33 or 97 times, respectively, the maximum intended human exposure based on blood auc levels. at doses at least 41 times the maximum intended human exposure based on blood auc levels, the gestation length was reduced in the dams, the incidence of dead fetuses, late resorptions, peri- and postnatal pup mortality was increased, and pup body weights were reduced. there are no adequate and well-controlled studies of lumigan ® 0.01% and 0.03% (bimatoprost ophthalmic solution) administration in pregnant women. because animal reproductive studies are not always predictive of human response lumigan ® should be administered during pregnancy only if th